BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence 2017;11:85-93. [PMID: 28138226 DOI: 10.2147/PPA.S127139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wang L, Chen P, Zheng C. Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B. Infect Drug Resist 2018;11:2179-85. [PMID: 30519055 DOI: 10.2147/IDR.S186719] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Wu Y, Fan J, Liao G, Xia M, Jiang D, Peng J, Zhang X, Liu H. Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Infect Genet Evol 2020;78:104124. [PMID: 31765828 DOI: 10.1016/j.meegid.2019.104124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Parmar NV, Glauser J. Systematic Review of Current Treatment and Prevention Strategies for Clostridium difficile. Curr Emerg Hosp Med Rep 2019;7:66-73. [DOI: 10.1007/s40138-019-00186-1] [Reference Citation Analysis]
5 Xie L, Liao G, Chen H, Xia M, Huang X, Fan R, Peng J, Zhang X, Liu H. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infect Dis 2019;19:640. [PMID: 31324231 DOI: 10.1186/s12879-019-4261-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2021:gutjnl-2020-323979. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis. 2017;215:581-589. [PMID: 28329347 DOI: 10.1093/infdis/jix025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
8 Cai S, Li Z, Yu T, Xia M, Peng J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist 2018;11:469-77. [PMID: 29662321 DOI: 10.2147/IDR.S163038] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
9 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
10 Liu J, Li T, Zhang L, Xu A. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. Hepatology. 2019;70:1045-1055. [PMID: 30561829 DOI: 10.1002/hep.30474] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 25.0] [Reference Citation Analysis]
11 Chen Y, Furuya-kanamori L, Doi SA, Ananthakrishnan AN, Kirk M. Clostridium difficile Infection and Risk of Colectomy in Patients with Inflammatory Bowel Disease: A Bias-adjusted Meta-analysis. Inflammatory Bowel Diseases 2017;23:200-7. [DOI: 10.1097/mib.0000000000000998] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 3.4] [Reference Citation Analysis]
12 Xia M, Liao G, Chen H, Wu Y, Fan R, Zhang X, Peng J. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol 2019;198:31-8. [PMID: 30503407 DOI: 10.1016/j.clim.2018.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845-854. [PMID: 31114265 DOI: 10.2147/idr.s195144] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]